EHA 2020 – Multiple Myeloma

Ixazomib-Based Therapy in Patients with RRMM Treated via an Early Access Program in Europe

Ixazomib provided as part of an early access program in Europe resulted in a 58% overall response rate in an observational multicenter cohort study (UVEA-IXA) supporting the effectiveness of the drug in a real-world setting. Read More ›

JNJ-4528 for the Treatment of Patients with RRMM: Update of CARTITUDE-1 Phase 1b Results

EHA 2020 – Multiple Myeloma

An update from the phase 1b/2 CARTITUDE study reveals early, deep, and durable responses and a manageable safety profile from treatment of patients with advanced RRMM with JNJ-4528 CAR T-cells. Read More ›

Teclistamab, a Novel Bispecific Antibody, for the Treatment of Advanced Relapsed/Refractory Multiple Myeloma: Early Promising Results

EHA 2020 – Multiple Myeloma

Based on early results of a dose-escalation study, teclistamab demonstrated an overall response rate of 67% at the highest dose, as well as reasonable tolerability with low incidence of high-grade cytokine release syndrome in patients with advanced relapsed/refractory multiple myeloma. Read More ›

EHA 2020 – Multiple Myeloma

Page 3 of 3